Interaction of Gut Microbiome and Host microRNAs with the Occurrence of Colorectal and Breast Cancer and Their Impact on Patient Immunity

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Breast cancer - WHO | World Health Organization [homepage on the Internet]. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer. Accessed June 14, 2021.
   Google Scholar
• Johnson KS, Conant EF, Soo MS. Molecular subtypes of breast cancer: a review for breast radiologists. J Breast Imaging. 2021;3(1):12–24. doi:10.1093/jbi/wbaa110
   Google Scholar
• Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol. 2009;36(3):237–249. doi:10.1053/j.seminoncol.2009.03.001
   PubMed Web of Science ®Google Scholar
• Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812–822. doi:10.1093/jnci/djt095
   PubMedGoogle Scholar
• Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013;5(Suppl 1):S2–S8.
   PubMedGoogle Scholar
• Durbecq V, Ameye L, Veys I, et al. A significant proportion of elderly patients develop hormone-dependent “luminal-B” tumors associated with aggressive characteristics. Crit Rev Oncol Hematol. 2008;67(1):80–92. doi:10.1016/j.critrevonc.2007.12.008
   PubMed Web of Science ®Google Scholar
• Seiler A, Chen MA, Brown RL, Fagundes CP. Obesity, dietary factors, nutrition, and breast cancer risk. Curr Breast Cancer Rep. 2018;10(1):14–27. doi:10.1007/s12609-018-0264-0
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Sung JJ, Ng SC, Chan FK, et al. An updated Asia Pacific consensus recommendations on colorectal cancer screening. Gut. 2015;64(1):121–132. doi:10.1136/gutjnl-2013-306503
   PubMed Web of Science ®Google Scholar
• Pourhoseingholi MA. Epidemiology and burden of colorectal cancer in Asia-Pacific region: what shall we do now? Transl Gastrointest Cancer. 2014;3(4):169–173. doi:10.3978/j.issn.2224-4778.2014.08.10
   Google Scholar
• Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691. doi:10.1136/gutjnl-2015-310912
   PubMed Web of Science ®Google Scholar
• Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89–103. doi:10.5114/pg.2018.81072
   PubMed Web of Science ®Google Scholar
• Ahnen DJ, Wade SW, Jones WF, et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89(2):216–224. doi:10.1016/j.mayocp.2013.09.006
   PubMed Web of Science ®Google Scholar
• Kyaw M, Sung JJ. Young-onset colorectal cancer in the Asia-Pacific region. Med J Aust. 2016;205(10):450–451. doi:10.5694/mja16.00957
   PubMed Web of Science ®Google Scholar
• Marley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016;7(3):105–114.
   PubMed Web of Science ®Google Scholar
• Campos FG. Colorectal cancer in young adults: a difficult challenge. World J Gastroenterol. 2017;23(28):5041–5044. doi:10.3748/wjg.v23.i28.5041
   PubMed Web of Science ®Google Scholar
• Dong L, Ren H. Blood-based DNA methylation biomarkers for early detection of colorectal cancer. J Proteomics Bioinform. 2018;11(6):120–126. doi:10.4172/jpb.1000477
   PubMedGoogle Scholar
• Bogaert J, Prenen H. Molecular genetics of colorectal cancer. Ann Gastroenterol. 2014;27(1):9–14.
   PubMedGoogle Scholar
• Jass JR. Colorectal cancer: a multi-pathway disease. Crit Rev Oncog. 2006;12(3–4):273–287. doi:10.1615/CritRevOncog.v12.i3-4.50
   PubMedGoogle Scholar
• Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest Cancer Res. 2012;5(1):19–27.
   PubMedGoogle Scholar
• Tariq K, Ghias K. Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med. 2016;13(1):120–135. doi:10.20892/j.issn.2095-3941.2015.0103
   PubMed Web of Science ®Google Scholar
• Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386(6625):623–627. doi:10.1038/386623a0
   PubMed Web of Science ®Google Scholar
• Carter JV, Galbraith NJ, Yang D, Burton JF, Walker SP, Galandiuk S. Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis. Br J Cancer. 2017;116(6):762–774. doi:10.1038/bjc.2017.12
   PubMed Web of Science ®Google Scholar
• Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA? RNA. 2005;11(12):1753–1761. doi:10.1261/rna.2248605
   PubMed Web of Science ®Google Scholar
• Frixa T, Donzelli S, Blandino G. Oncogenic microRNAs: key players in malignant transformation. Cancers. 2015;7(4):2466–2485. doi:10.3390/cancers7040904
   PubMed Web of Science ®Google Scholar
• Grammatikakis I, Gorospe M, Abdelmohsen K. Modulation of cancer traits by tumor suppressor microRNAs. Int J Mol Sci. 2013;14(1):1822–1842. doi:10.3390/ijms14011822
   PubMed Web of Science ®Google Scholar
• Lopez-Camarillo C, Marchat LA, Arechaga-Ocampo E, et al. MetastamiRs: non-coding microRNAs driving cancer invasion and metastasis. Int J Mol Sci. 2012;13(2):1347–1379. doi:10.3390/ijms13021347
   PubMed Web of Science ®Google Scholar
• Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM. Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta. 2014;1845(2):255–265. doi:10.1016/j.bbcan.2014.02.002
   PubMed Web of Science ®Google Scholar
• Li M, Chen WD, Wang YD. The roles of the gut microbiota-miRNA interaction in the host pathophysiology. Mol Med. 2020;26(1):101. doi:10.1186/s10020-020-00234-7
   PubMed Web of Science ®Google Scholar
• Kho ZY, Lal SK. The human gut microbiome - a potential controller of wellness and disease. Front Microbiol. 2018;9:1835. doi:10.3389/fmicb.2018.01835
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zeng Y, Zeng D, et al. Probiotics and microRNA: their roles in the host-microbe interactions. Front Microbiol. 2021;11:604462. doi:10.3389/fmicb.2020.604462
   PubMed Web of Science ®Google Scholar
• Allegra A, Musolino C, Tonacci A, Pioggia G, Gangemi S. Interactions between the microRNAs and microbiota in cancer development: roles and therapeutic opportunities. Cancers. 2020;12(4):805. doi:10.3390/cancers12040805
   PubMed Web of Science ®Google Scholar
• Yuan C, Burns MB, Subramanian S, Blekhman R. Interaction between host microRNAs and the gut microbiota in colorectal cancer. mSystems. 2018;3(3):e00205–e00217. doi:10.1128/mSystems.00205-17
   PubMed Web of Science ®Google Scholar
• Williams MR, Stedtfeld RD, Tiedje JM, Hashsham SA. MicroRNAs-based inter-domain communication between the host and members of the gut microbiome. Front Microbiol. 2017;8:1896. doi:10.3389/fmicb.2017.01896
   PubMed Web of Science ®Google Scholar
• Karius T, Schnekenburger M, Dicato M, Diederich M. MicroRNAs in cancer management and their modulation by dietary agents. Biochem Pharmacol. 2012;83(12):1591–1601. doi:10.1016/j.bcp.2012.02.004
   PubMed Web of Science ®Google Scholar
• Bi K, Zhang X, Chen W, Diao H. MicroRNAs regulate intestinal immunity and gut microbiota for gastrointestinal health: a comprehensive review. Genes. 2020;11(9):1075. doi:10.3390/genes11091075
   PubMed Web of Science ®Google Scholar
• Ishida M, Selaru FM. miRNA-based therapeutic strategies. Curr Anesthesiol Rep. 2013;1(1):63–70. doi:10.1007/s40139-012-0004-5
   PubMedGoogle Scholar
• Pedroza-Torres A, Romero-Córdoba SL, Justo-Garrido M, et al. MicroRNAs in tumor cell metabolism: roles and therapeutic opportunities. Front Oncol. 2019;9:1404. doi:10.3389/fonc.2019.01404
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–10518. doi:10.1073/pnas.0804549105
   PubMed Web of Science ®Google Scholar
• Shimomura A, Shiino S, Kawauchi J, et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci. 2016;107(3):326–334. doi:10.1111/cas.12880
   PubMed Web of Science ®Google Scholar
• Ng EK, Li R, Shin VY, et al. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One. 2013;8(1):e53141. doi:10.1371/journal.pone.0053141
   PubMed Web of Science ®Google Scholar
• Shin VY, Siu JM, Cheuk I, Ng EK, Kwong A. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer. 2015;112(11):1751–1759. doi:10.1038/bjc.2015.143
   PubMed Web of Science ®Google Scholar
• Peña-Chilet M, Martínez MT, Pérez-Fidalgo JA, et al. MicroRNA profile in very young women with breast cancer. BMC Cancer. 2014;14:529. doi:10.1186/1471-2407-14-529
   PubMedGoogle Scholar
• Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010;119(3):586–593. doi:10.1016/j.ygyno.2010.07.021
   PubMed Web of Science ®Google Scholar
• Bhat SA, Majid S, Hassan T. MicroRNAs and its emerging role as breast cancer diagnostic marker - A review. Adv Biomark Sci Technol. 2019;1:1–8. doi:10.1016/j.abst.2019.05.001
   Google Scholar
• Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 2011;57(1):84–91. doi:10.1373/clinchem.2010.151845
   PubMed Web of Science ®Google Scholar
• Cortez MA, Welsh JW, Calin GA. Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res. 2012;195:151–161. doi:10.1007/978-3-642-28160-0_13
   PubMedGoogle Scholar
• Niu J, Shi Y, Tan G, et al. DNA damage induces NF-κB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion. J Biol Chem. 2012;287(26):21783–21795. doi:10.1074/jbc.M112.355495
   PubMed Web of Science ®Google Scholar
• Tsai HP, Huang SF, Li CF, Chien HT, Chen SC. Differential microRNA expression in breast cancer with different onset age. PLoS One. 2018;13(1):e0191195. doi:10.1371/journal.pone.0191195
   PubMed Web of Science ®Google Scholar
• Zelli V, Compagnoni C, Capelli R, et al. Circulating microRNAs as prognostic and therapeutic biomarkers in breast cancer molecular subtypes. J Pers Med. 2020;10(3):98. doi:10.3390/jpm10030098
   PubMed Web of Science ®Google Scholar
• Khalighfard S, Alizadeh AM, Irani S, Omranipour R. Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. Sci Rep. 2018;8(1):17981. doi:10.1038/s41598-018-36321-3
   PubMedGoogle Scholar
• McAnena P, Tanriverdi K, Curran C, et al. Circulating microRNAs miR-331 and miR-195 differentiate local Luminal A from metastatic breast cancer. BMC Cancer. 2019;19:436. doi:10.1186/s12885-019-5636-y
   PubMed Web of Science ®Google Scholar
• Søkilde R, Persson H, Ehinger A, et al. Refinement of breast cancer molecular classification by miRNA expression profiles. BMC Genomics. 2019;20(1):503. doi:10.1186/s12864-019-5887-7
   PubMedGoogle Scholar
• Cecene G, Ak S, Eskiler GG, et al. Circulating miR-195 as a therapeutic biomarker in Turkish breast cancer patients. Asian Pac J Cancer Prev. 2016;17(9):4241–4246.
   PubMedGoogle Scholar
• Sareyeldin RM, Gupta I, Al-Hashimi I, et al. Gene expression and miRNAs profiling: function and regulation in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Cancers. 2019;11(5):646. doi:10.3390/cancers11050646
   PubMed Web of Science ®Google Scholar
• Zeng RC, Zhang W, Yan X, et al. Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer. Med Oncol. 2013;30(1):477. doi:10.1007/s12032-013-0477-z
   PubMed Web of Science ®Google Scholar
• Gasparini P, Lovat F, Fassan M, et al. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci U S A. 2014;111(12):4536–4541. doi:10.1073/pnas.1402604111
   PubMed Web of Science ®Google Scholar
• Kleivi Sahlberg K, Bottai G, Naume B, et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res. 2015;21(5):1207–1214. doi:10.1158/1078-0432.CCR-14-2011
   PubMed Web of Science ®Google Scholar
• Shaheen J, Shahid S, Shahzadi S, Akhtar MW, Sadaf S. Identification of circulating miRNAs as noninvasive biomarkers of triple negative breast cancer in the population of Pakistan. Pakistan J Zool. 2019;51(3):1113–1121. doi:10.17582/journal.pjz/2019.51.3.1113.1121
   Web of Science ®Google Scholar
• Nama S, Muhuri M, Di Pascale F, et al. MicroRNA-138 is a prognostic biomarker for triple-negative breast cancer and promotes tumorigenesis via TUSC2 repression. Sci Rep. 2019;9(1):12718. doi:10.1038/s41598-019-49155-4
   PubMedGoogle Scholar
• Li HY, Liang JL, Kuo YL, et al. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Breast Cancer Res. 2017;19(1):133. doi:10.1186/s13058-017-0918-2
   PubMedGoogle Scholar
• Piasecka D, Braun M, Kordek R, Sadej R, Romanska H. MicroRNAs in regulation of triple-negative breast cancer progression. J Cancer Res Clin Oncol. 2018;144(8):1401–1411. doi:10.1007/s00432-018-2689-2
   PubMed Web of Science ®Google Scholar
• Gupta I, Rizeq B, Vranic S, Moustafa AA, Al Farsi H. Circulating miRNAs in HER2-positive and triple negative breast cancers: potential biomarkers and therapeutic targets. Int J Mol Sci. 2020;21(18):6750. doi:10.3390/ijms21186750
   PubMed Web of Science ®Google Scholar
• Wang W, Luo YP. MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential. J Zhejiang Univ Sci B. 2015;16(1):18–31. doi:10.1631/jzus.B1400184
   PubMed Web of Science ®Google Scholar
• Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 2015;5(10):1122–1143. doi:10.7150/thno.11543
   PubMed Web of Science ®Google Scholar
• van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 2015;17:21. doi:10.1186/s13058-015-0526-y
   PubMed Web of Science ®Google Scholar
• Banerjee S, Tian T, Wei Z, et al. Distinct microbial signatures associated with different breast cancer types. Front Microbiol. 2018;9:951. doi:10.3389/fmicb.2018.00951
   PubMed Web of Science ®Google Scholar
• Banerjee S, Wei Z, Tian T, et al. Prognostic correlations with the microbiome of breast cancer subtypes. Cell Death Dis. 2021;12(9):831. doi:10.1038/s41419-021-04092-x
   PubMed Web of Science ®Google Scholar
• Parida S, Sharma D. The microbiome-estrogen connection and breast cancer risk. Cells. 2019;8(12):1642. doi:10.3390/cells8121642
   PubMed Web of Science ®Google Scholar
• Fernández MF, Reina-Pérez I, Astorga JM, Rodríguez-Carrillo A, Plaza-Díaz J, Fontana L. Breast cancer and its relationship with the microbiota. Int J Environ Res Public Health. 2018;15(8):1747. doi:10.3390/ijerph15081747
   PubMed Web of Science ®Google Scholar
• Zhao H, Chen J, Li X, Sun Q, Qin P, Wang Q. Compositional and functional features of the female premenopausal and postmenopausal gut microbiota. FEBS Lett. 2019;593(18):2655–2664. doi:10.1002/1873-3468.13527
   PubMed Web of Science ®Google Scholar
• Zhang J, Xia Y, Sun J. Breast and gut microbiome in health and cancer. Genes Dis. 2020;8(5):581–589. doi:10.1016/j.gendis.2020.08.002
   PubMed Web of Science ®Google Scholar
• Luu TH, Michel C, Bard JM, Dravet F, Nazih H, Bobin-Dubigeon C. Intestinal proportion of Blautia sp. is associated with clinical stage and histoprognostic grade in patients with early-stage breast cancer. Nutr Cancer. 2017;69(2):267–275. doi:10.1080/01635581.2017.1263750
   PubMed Web of Science ®Google Scholar
• Laborda-Illanes A, Sanchez-Alcoholado L, Dominguez-Recio ME, et al. Breast and gut microbiota action mechanisms in breast cancer pathogenesis and treatment. Cancers. 2020;12(9):2465. doi:10.3390/cancers12092465
   PubMed Web of Science ®Google Scholar
• Urbaniak C, Gloor GB, Brackstone M, et al. The Microbiota of breast tissue and its association with breast cancer. Appl Environ Microbiol. 2016;82(16):5039–5048. doi:10.1128/AEM.01235-16
   PubMed Web of Science ®Google Scholar
• Urbaniak C, Cummins J, Brackstone M, et al. Microbiota of human breast tissue. Appl Environ Microbiol. 2014;80(10):3007–3014. doi:10.1128/AEM.00242-14
   PubMed Web of Science ®Google Scholar
• Schwabe R, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800–812. doi:10.1038/nrc3610
   PubMed Web of Science ®Google Scholar
• Fuhrman BJ, Feigelson HS, Flores R, et al. Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. J Clin Endocrinol Metab. 2014;99(12):4632–4640. doi:10.1210/jc.2014-2222
   PubMed Web of Science ®Google Scholar
• Zengul AG, Demark-Wahnefried W, Barnes S, et al. Associations between dietary fiber, the fecal microbiota and estrogen metabolism in postmenopausal women with breast cancer. Nutr Cancer. 2021;73(7):1108–1117. doi:10.1080/01635581.2020.1784444
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast. 2015;24(02):S36–40. doi:10.1016/j.breast.2015.07.009
   PubMedGoogle Scholar
• Schee K, Fodstad Ø, Flatmark K. MicroRNAs as biomarkers in colorectal cancer. Am J Pathol. 2010;177(4):1592–1599. doi:10.2353/ajpath.2010.100024
   PubMed Web of Science ®Google Scholar
• Reid JF, Sokolova V, Zoni E, et al. miRNA profiling in colorectal cancer highlights miR-1. Involvement in MET-dependent proliferation. Mol Cancer Res. 2012;10(4):504–515. doi:10.1158/1541-7786.MCR-11-0342
   PubMed Web of Science ®Google Scholar
• To KK, Tong CW, Wu M, Cho WC. MicroRNAs in the prognosis and therapy of colorectal cancer: from bench to bedside. World J Gastroenterol. 2018;24(27):2949–2973. doi:10.3748/wjg.v24.i27.2949
   PubMed Web of Science ®Google Scholar
• Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma miR141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011;6(3):e17745. doi:10.1371/journal.pone.0017745
   PubMed Web of Science ®Google Scholar
• Yu W, Wang Z, Shen LI, Wei Q. Circulating microRNA-21 as a potential diagnostic marker for colorectal cancer: a meta-analysis. Mol Clin Oncol. 2016;4(2):237–244. doi:10.3892/mco.2015.702
   PubMed Web of Science ®Google Scholar
• Du B, Wu D, Yang X, et al. The expression and significance of microRNA in different stages of colorectal cancer. Medicine. 2018;97(5):e9635. doi:10.1097/MD.0000000000009635
   PubMed Web of Science ®Google Scholar
• Toiyama Y, Takahashi M, Hur K, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105(12):849–859. doi:10.1093/jnci/djt101
   PubMedGoogle Scholar
• Kubota N, Taniguchi F, Nyuya A, et al. Upregulation of microRNA-31 is associated with poor prognosis in patients with advanced colorectal cancer. Oncol Lett. 2020;19(4):2685–2694. doi:10.3892/ol.2020.11365
   PubMed Web of Science ®Google Scholar
• Nosho K, Igarashi H, Nojima M, et al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis. 2014;35(4):776–783. doi:10.1093/carcin/bgt374
   PubMed Web of Science ®Google Scholar
• Zou S, Fang L, Lee MH. Dysbiosis of gut microbiota in promoting the development of colorectal cancer. Gastroenterol Rep. 2018;6(1):1–12. doi:10.1093/gastro/gox031
   Google Scholar
• Wang T, Cai G, Qiu Y, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2012;6(2):320–329. doi:10.1038/ismej.2011.109
   PubMed Web of Science ®Google Scholar
• Sánchez-Alcoholado L, Ramos-Molina B, Otero A, et al. The role of the gut microbiome in colorectal cancer development and therapy response. Cancers. 2020;12(6):1406. doi:10.3390/cancers12061406
   PubMed Web of Science ®Google Scholar
• Cheng Y, Ling Z, Li L. The intestinal microbiota and colorectal cancer. Front Immunol. 2020;11:615056. doi:10.3389/fimmu.2020.615056
   PubMed Web of Science ®Google Scholar
• Dai Z, Zhang J, Wu Q, et al. The role of microbiota in the development of colorectal cancer. Int J Cancer. 2019;145(8):2032–2041. doi:10.1002/ijc.32017
   PubMed Web of Science ®Google Scholar
• Raskov H, Burcharth J, Pommergaard HC. Linking gut microbiota to colorectal cancer. J Cancer. 2017;8(17):3378–3395. doi:10.7150/jca.20497
   PubMed Web of Science ®Google Scholar
• Lu Y, Segelman J, Nordgren A, Lindström L, Frisell J, Martling A. Increased risk of colorectal cancer in patients diagnosed with breast cancer in women. Cancer Epidemiol. 2016;41:57–62. doi:10.1016/j.canep.2016.01.006
   PubMed Web of Science ®Google Scholar
• Abu-Sbeih H, Ali FS, Ge PS, et al. Patients with breast cancer may be at higher risk of colorectal neoplasia. Ann Gastroenterol. 2019;32(4):400–406. doi:10.20524/aog.2019.0387
   PubMed Web of Science ®Google Scholar
• Yan X, Chen X, Liang H, et al. miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer. 2014;13:220. doi:10.1186/1476-4598-13-220
   PubMed Web of Science ®Google Scholar
• Kundaktepe BP, Sozer V, Papila C, et al. Associations between miRNAs and two different cancers: breast and colon. Cancer Manag Res. 2020;12:871–879. doi:10.2147/CMAR.S227628
   PubMed Web of Science ®Google Scholar
• Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring, and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4(3):143–159. doi:10.1002/emmm.201100209
   PubMed Web of Science ®Google Scholar
• Cho S, Tai JW, Lu LF. MicroRNAs and their targetomes in tumor-immune communication. Cancers. 2020;12(8):2025. doi:10.3390/cancers12082025
   PubMed Web of Science ®Google Scholar
• Yi M, Xu L, Jiao Y, Luo S, Li A, Wu K. The role of cancer-derived microRNAs in cancer immune escape. J Hematol Oncol. 2020;13(1):25. doi:10.1186/s13045-020-00848-8
   PubMed Web of Science ®Google Scholar
• Omar HA, El-Serafi AT, Hersi F, et al. Immunomodulatory microRNAs in cancer: targeting immune checkpoints and the tumor microenvironment. FEBS J. 2019;286(18):3540–3557. doi:10.1111/febs.15000
   PubMed Web of Science ®Google Scholar
• Colangelo T, Polcaro G, Ziccardi P, et al. Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer. Cell Death Dis. 2016;7(2):e2120. doi:10.1038/cddis.2016.28
   PubMed Web of Science ®Google Scholar
• Pesce S, Greppi M, Ferretti E, et al. miRNAs in NK cell-based immune responses and cancer immunotherapy. Front Cell Dev Biol. 2020;8:119. doi:10.3389/fcell.2020.00119
   PubMed Web of Science ®Google Scholar
• Bose M, Mukherjee P. Role of microbiome in modulating immune responses in cancer. Mediators Inflamm. 2019;2019:4107917. doi:10.1155/2019/4107917
   PubMed Web of Science ®Google Scholar
• Ge Y, Wang X, Guo Y, et al. Gut microbiota influence tumor development and alter interactions with the human immune system. J Exp Clin Cancer Res. 2021;40(1):42. doi:10.1186/s13046-021-01845-6
   PubMed Web of Science ®Google Scholar
• Zhang L, Pan J, Chen W, Jiang J, Huang J. Chronic stress-induced immune dysregulation in cancer: implications for initiation, progression, metastasis, and treatment. Am J Cancer Res. 2020;10(5):1294–1307.
   PubMed Web of Science ®Google Scholar
• Tahaghoghi-Hajghorbani S, Zafari P, Masoumi E, et al. The role of dysregulated immune responses in COVID-19 pathogenesis. Virus Res. 2020;290:198197. doi:10.1016/j.virusres.2020.198197
   PubMed Web of Science ®Google Scholar
• Jyotsana N, King MR. The Impact of COVID-19 on cancer risk and treatment. Cell Mol Bioeng. 2020;13(4):285–291. doi:10.1007/s12195-020-00630-3
   PubMed Web of Science ®Google Scholar
• Niu P, Lei F, Gu J. Colorectal cancer and COVID-19: do we need to raise awareness and vigilance? Cancer. 2021;127(6):979–980. doi:10.1002/cncr.33217
   PubMed Web of Science ®Google Scholar
• Liu C, Wang K, Zhang M, et al. High expression of ACE2 and TMPRSS2 and clinical characteristics of COVID-19 in colorectal cancer patients. NPJ Precis Oncol. 2021;5(1):1. doi:10.1038/s41698-020-00139-y
   PubMed Web of Science ®Google Scholar
• Nersisyan S, Engibaryan N, Gorbonos A, Kirdey K, Makhonin A, Tonevitsky A. Potential role of cellular miRNAs in coronavirus-host interplay. PeerJ. 2020;8:e9994. doi:10.7717/peerj.9994
   PubMed Web of Science ®Google Scholar
• Sardar R, Satish D, Birla S, Gupta D. Comparative analyses of SAR-CoV2 genomes from different geographical locations and other coronavirus family genomes reveals unique features potentially consequential to host-virus interaction and pathogenesis. bioRxiv. 2020. doi:10.1101/2020.03.21.001586
   Google Scholar
• Chauhan N, Jaggi M, Chauhan SC, Yallapu MM. COVID-19: fighting the invisible enemy with microRNAs. Expert Rev Anti Infect Ther. 2021;19(2):137–145. doi:10.1080/14787210.2020.1812385
   PubMed Web of Science ®Google Scholar
• Fani M, Zandi M, Ebrahimi S, Soltani S, Abbasi S. The role of miRNAs in COVID-19 disease. Future Virol. 2021;16:301–306. doi:10.2217/fvl-2020-0389
   Web of Science ®Google Scholar
• Francescangeli F, De Angelis ML, Zeuner A. COVID-19: a potential driver of immune-mediated breast cancer recurrence? Breast Cancer Res. 2020;22(1):117. doi:10.1186/s13058-020-01360-0
   PubMed Web of Science ®Google Scholar
• Yang Y, Alderman C, Sehlaoui A, Xiao Y, Wang W. MicroRNAs as immunotherapy targets for treating gastroenterological cancers. Can J Gastroenterol Hepatol. 2018;2018:9740357. doi:10.1155/2018/9740357
   PubMed Web of Science ®Google Scholar
• Paladini L, Fabris L, Bottai G, Raschioni C, Calin GA, Santarpia L. Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res. 2016;35:103. doi:10.1186/s13046-016-0375-2
   PubMed Web of Science ®Google Scholar
• He W, Wang C, Mu R, et al. MiR-21 is required for antitumor immune response in mice: an implication for its bi-directional roles. Oncogene. 2017;36(29):4212–4223. doi:10.1038/onc.2017.62
   PubMed Web of Science ®Google Scholar
• Michaille JJ, Awad H, Fortman EC, Efanov AA, Tili E. miR-155 expression in antitumor immunity: the higher, the better? Genes Chromosomes Cancer. 2019;58(4):208–218. doi:10.1002/gcc.22698
   PubMed Web of Science ®Google Scholar
• Dai Z, Zhang J, Wu Q, et al. Intestinal microbiota: a new force in cancer immunotherapy. Cell Commun Signal. 2020;18(1):90. doi:10.1186/s12964-020-00599-6
   PubMed Web of Science ®Google Scholar
• Kim E, Ahn H, Park H. A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer. Mamm Genome. 2021;32:223–231. doi:10.1007/s00335-021-09867-3
   PubMed Web of Science ®Google Scholar
• Li W, Deng Y, Chu Q, Zhang P. Gut microbiome and cancer immunotherapy. Cancer Lett. 2019;447:41–47. doi:10.1016/j.canlet.2019.01.015
   PubMed Web of Science ®Google Scholar
• Sedighi M, Zahedi Bialvaei A, Hamblin MR, et al. Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities. Cancer Med. 2019;8(6):3167–3181. doi:10.1002/cam4.2148
   PubMed Web of Science ®Google Scholar